Commission on Cancer Standard 3.3 - Survivorship Care Plans

AONN+ Blog published on November 21, 2017 in CoC Standards, Survivorship
Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
Editor-in-Chief, JONS; Co-Founder, AONN+; University Distinguished Service Professor of Breast Cancer, Professor of Surgery, Johns Hopkins University School of Medicine; Co-Developer, Work Stride-Managing Cancer at Work, Johns Hopkins Healthcare Solutions

I was privileged to chair a task force for the purpose of revisiting this standard and determining what issues lay within it that are barriers to cancer centers being able to achieve it. Upon the creation of such recommended changes, another task force for which I also served, reviewed these recommendations, and, I am pleased to say, approved them. Hot off the press, here is information that you get to hear even before it is announced to accredited facilities.

 

 
Related Items
Acute Survivorship
Kimberlee Rowett, DNP (c), MSN, MBA, RN
Webinars published on July 3, 2024 in Survivorship
Stages of Survivorship: Extended Survivorship
Jason King, RN, BSN, OCN
Webinars published on July 3, 2024 in Survivorship
The objectives of this webinar session are:
  • Define the “extended” survivorship phase.
  • Review cancer survivor facts and figures.
  • Identify immediate effects of cancer treatment.
  • Identify strategies for addressing the unique needs of cancer survivors in this stage.
  • Discuss the navigator’s role in evaluating, assessing, and planning follow-up care.
Stages of Survivorship: Permanent/Long-Term Survivorship
Megan Solinger, MHS, MA, OPN-CG, Pam Plasket, RN, BSN, OCN, CHPN
Webinars published on July 3, 2024 in Survivorship
The objectives of this webinar session are:
  • Define the “permanent/long-term” survivorship phase
  • Review cancer survivor facts and figures
  • Identify the prevalent concerns/needs of survivors in this phase
  • Identify strategies to address survivor needs in this phase
  • Discuss navigator’s role in evaluating, assessing and planning follow-up care
  • Discuss special considerations for the AYA and transplant population in this phase